Dalrada Corporation (OTCQB: DFCO, "Dalrada") proudly announces the openings of Dalrada Health's two new West Coast facilities with Sòlas Rejuvenation + Wellness ("Sòlas”) and Empower Genomics' state-of-the-art testing laboratory.
Dalrada's Chairman and CEO, Brian Bonar, states, "Creating impactful healthcare solutions is Dalrada Health's goal. The openings of Sòlas Rejuvenation + Wellness and Empower Genomics™ laboratory establishes public and private access to precision resources for personalized health and wellness."
Sòlas is Dalrada Health's flagship walk-in health clinic and therapy center. The state-of-the-art facility hosts advanced medical-based practices, customized anti-aging and regenerative therapies as well as traditional aesthetic procedures that empower people to thrive and lead the life they deserve.
Guests of Sòlas can select from a wide range of private, tailored, state-of-the-art services and therapies that currently include:
- Aesthetics
- Regenerative Therapy
- Healthy Habits
- IV Therapy Lounge
- Hormone Re-balancing
- Men's Health and Wellness
- Women's Health and Wellness
- Customized Services
With convenient parking and easy access, Sòlas is located in a 56,510-square foot medical and dental center in the community of Poway, California. Adjacent to Palomar Hospital and popular medical imaging and surgery centers, Sòlas' neighbors include more than 100 physicians in the surrounding buildings. The Poway Chamber of Commerce hosted a ribbon-cutting ceremony and welcomed Sòlas to the north San Diego community on Thursday, November 4th.
Empower Genomics™, a product suite of Dalrada Health, believes in harnessing the power of knowledge through cutting-edge scientific technology using advanced testing. The new Empower laboratory provides immediate capabilities to offer on-site COVID-19 testing services. This expansion into the virology testing industry is a testament to the organization’s continued mission to address global problems. The high-throughput laboratory is located in San Diego, CA, offering the convenience to thousands of businesses and event venues. The Company plans to expand the capabilities of the laboratory beyond COVID-19 into the future.
Dalrada Health believes that cutting-edge scientific technology is empowering. And empowering people to understand their uniqueness better builds a blueprint of health and wellness for their future. Empower Genomics™ provides tomorrow's knowledge today. For additional insight on Empower Genomics™ individual tests and practitioner custom label programs, please visit www.empowergenomics.com.
Sòlas Rejuvenation + Wellness' dedicated service-focused, health-first approach enriches lives with advanced rejuvenation techniques and robust wellness programs. Sòlas provides a distinct suite of customizable programs that include specialized supplements, nutrition/fitness analysis and consultation, and DNA testing. For additional details, kindly visit www.solasrejuvenation.com.
Continuously building on its core life sciences, technology, and engineering practices, Dalrada brings innovative products and services to a complex new world. As consumers, businesses, and governments seek alternative solutions, Dalrada's subsidiaries respond with affordable, accessible, and impactful innovations. Additional details are available at www.dalrada.com.
About Dalrada Health
A wholly-owned subsidiary of Dalrada Corporation, Dalrada Health is focused on solving health problems around the world. The Company develops products and services that address the unmet needs of consumers due to accessibility, affordability, or availability. With operations in the U.S., Malaysia, and India, Dalrada Health can reach underserved markets through strong partnerships and the development of efficient supply chains. Dalrada Health is committed to solving universal health problems through improved methodologies resulting in products and services that benefit the global marketplace. For details, visit www.dalradahealth.com.
About Dalrada (DFCO)
With perseverance, valor, dedication, and vision, Dalrada Corporation is dedicated to tackling worldwide challenges of today and tomorrow.
Dalrada is a global company that operates under the tenet of creating impactful innovations that matter for the world. The Company works continually to produce disruptive solutions that bridge the gap of accessibility and accelerate positive change for current and future generations.
Established in 1982, the Company has since grown its footprint to include the business divisions: Dalrada Health, Dalrada Precision, and Dalrada Technologies. Each of Dalrada's subsidiaries actively produces affordable and accessible world-class solutions to global problems. For more information, please visit www.dalrada.com.
Disclaimer
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors and will be dependent upon a variety of factors including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005515/en/
Contacts
Denise Mahaffey
858.283.1253
inquiries@dalrada.com
